What are annual sales of Humira?
In 2020 Humira pulled in $19.83 billion in revenue for a year-over-year increase of 3.5%.
How much Humira is sold?
Abbvie’s top product Humira AbbVie’s Humira has increased its revenue from 2011 to 2018, generating 7.9 billion U.S. dollars in 2011, a record high of 19.9 billion U.S. dollars in 2018, and 19.8 billion in 2020. Humira is expected to continue its success in the near future.
Why is Humira the top selling drug?
By the numbers: Humira, the rheumatoid arthritis blockbuster made by AbbVie, continues to generate more revenue than any other drug, due to AbbVie extending U.S. patents and consequently retaining higher U.S. prices.
What is the most sold medication in the US?
Humira
The Medications
| Medication | Pharmaceutical Company | U.S. Sales |
|---|---|---|
| 1. Humira (Adalimumab) | AbbVie | $13.7 billion |
| 2. Eliquis (Apixaban) | Bristol-Myers Squibb/Pfizer2 | $5.61 billion |
| 3. Revlimid (Lenalidomide) | Celgene | $6.47 billion |
| 4. Keytruda (Pembrolizumab) | Merck | $4.15 billion |
How much does AbbVie make on Humira?
Financial Release
| AbbVie Inc. Key Product Revenues Quarter Ended March 31, 2021 (Unaudited) | ||
|---|---|---|
| U.S. | Total | |
| ADJUSTED NET REVENUESc | $9,675 | $12,935 |
| Immunology | 4,633 | 5,744 |
| Humira | 3,907 | 4,867 |
How long is the patent on Humira?
39 years
I-MAK in 2018 found AbbVie filed 247 patent applications for Humira and won patents that could have protected the medicine for up to 39 years. The drug’s price jumped 144% since 2012.
What is world’s best selling medicine?
Pharma’s top 10 best-selling drugs of 2019
- Humira — $19.6 billion. (AbbVie, Eisai)
- Keytruda — $11.1 billion. (Merck & Co.)
- Revlimid — $9.4 billion. (Bristol Myers Squibb, Celgene)
- Opdivo — $8 billion.
- Eliquis — $7.9 billion.
- Eylea — $7.5 billion.
- Enbrel — $7.2 billion.
- Avastin — $7.1 billion.
What does Humira treat?
HUMIRA is a prescription medicine used to treat moderate to severe Crohn’s disease (CD) in adults and children 6 years of age and older.
Is there a biosimilar for Humira?
Currently, there an’t any biosimilars to Humira on the market in the U.S., although six have been approved by the FDA and may come on the market in 2023.
How big is the global market for Humira?
Globally, the size of the Humira market is expected to grow at a vibrant CAGR between 2020 to 2025. Humira was initially approved in the United States and is now available in more than 60 countries.
How much money does AbbVie make with Humira?
In 2019, Humira hit $19.73 billion in sales for AbbVie in what will almost certainly be the drug’s zenith. Biosimilars have already hit in Europe, and AbbVie is expecting U.S. copycats to storm stateside sales beginning in 2023. All of that competition could drop Humira to $6.83 billion in sales in 2026, according to Evaluate Pharma.
Are there any biosimilars coming out for Humira?
Humira faced its first U.S. biosimilar challengers in mid-2019. (AbbVie) Another year, another run at the top of the sales chart for AbbVie’s megablockbuster anti-TNF immunology med Humira.
Who are the major players in the Humira market?
Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities Pfizer, Amgen, Novartis AG, Boehringer Ingelheim GmbH, Mylan N.V., and AbbVie among others.